Drug
Nalbuphine ER
Status:
Phase 2
Condition:
Chronic Cough
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Nalbuphine ER is a mu opioid receptor antagonist (blocker) and a kappa opioid receptor agonist (activator).
Study Purpose
This is a multicenter randomized, double-blind, placebo-controlled, parallel, 4-arm study of nalbuphine ER (NAL ER).
This drug has no clinical trials actively recruiting patients at this time.